AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

MYGN · NASDAQ · Medical - Diagnostics & Research

Myriad Genetics (MYGN)

Offers hereditary cancer, tumor profiling, prenatal, and GeneSight pharmacogenomic tests.

$4.17

vs last close+0.14 (+3.61%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	192	197	202	212	213	211	196	213	206	210	200	191
Cost of revenue	58	62	65	64	64	60	62	61	62	63	63	64
Gross profit	134	135	138	147	150	151	134	152	144	147	138	127
	194	166	166	184	170	190	163	481	167	153	168	166
Research & development	24	21	25	27	29	32	28	26	28	26	27	25
	136	33	141	145	139	136	136	139	139	124	136	141
Selling & marketing	0	0	69	73	70	284	69	72	71	69	74	83
General & administrative	136	33	71	72	69	−148	67	67	68	56	62	58
Other expenses	34	113	0	12	2	22	0	317	0	3	5	0
Operating income	−60	−31	−28	−37	−20	−39	−29	−329	−23	−6	−31	−39
	−1	−1	2	−1	−1	0	0	−1	−3	−3	−3	−4
Interest income	1	1	1	0	0	0	0	0	1	1	1	0
Interest expense	1	1	1	1	1	1	1	2	4	4	4	4
Other non-operating income	0	0	−3	0	0	−1	0	0	−1	−1	−1	0
Income before tax	−61	−32	−26	−37	−21	−39	−29	−331	−26	−9	−34	−43
Income tax expense	0	−1	0	−1	1	3	−29	0	1	−1	0	1
Net income from continuing operations	−61	−31	−26	−37	−22	−43	0	−331	−27	−8	−34	−43
Net income	−61	−31	−26	−37	−22	−43	0	−331	−27	−8	−34	−43
EPS, basic	−$0.75	−$0.36	−$0.29	−$0.41	−$0.24	−$0.47	−$0.00	−$3.57	−$0.29	−$0.08	−$0.36	−$0.46
EPS, diluted	−$0.75	−$0.36	−$0.29	−$0.41	−$0.24	−$0.47	−$0.00	−$3.57	−$0.29	−$0.08	−$0.36	−$0.46
Weighted average shares, basic	82	86	90	91	91	91	91	93	93	93	94	95
Weighted average shares, diluted	82	86	90	91	91	91	91	93	93	93	94	95
EBITDA	−46	−16	−10	−21	−5	−24	−14	−315	−10	8	−18	−26
Depreciation & amortization	14	15	16	15	16	15	14	14	13	13	13	13
EBIT	−60	−31	−25	−36	−20	−38	−29	−329	−22	−5	−30	−39